Background Safety concerns exist when using triptansto treat patients with cardiac contraindications. –Triptans cause vasoconstriction, a safety concern for migraineurswith cardiovascular (CV) disease or other cardiac risk factors. –All triptans contain contraindications in their package inserts to avoid use in patients with cardiac conditions. •Previous research indicates that clinicians are less likely to prescribe triptansin patients with CV disease or CV risk factors. Limited research has examined the proportion of migraine patients with cardiovascular disease or those individuals who were concurrently treated with triptans
Use of triptans and associated factors in subjects with definite or probable migraine: Prevalence Ra...
Sumatriptan is an agonist of 5-hydroxytryptamine type-1 (5HT1) receptors that is widely used as a mi...
Migraine might be associated with high blood pressure (BP), which can cause more severe and more dif...
Background Safety concerns exist when using triptansto treat patients with cardiac contraindications...
Background: Apart from the underlying cardiovascular (CV) risk associated with migraine, both tripta...
Objective. To examine the association between the cardiovascular (CV) risk factors and triptans use ...
The article highlights the issues of safety when using triptans in the treatment of migraine and the...
The efficacy and safety of triptans in the absence of contraindications have been proved. Neverthele...
AbstractBackgroundIdentifying migraineurs by triptan utilization we studied risk for stroke in migra...
The incidence of stroke, cardiovascular events, and death among 63,575 patients with migraine was co...
Triptans are an established treatment for acute migraine attacks. By activating 5HT1B/1D receptors t...
The triptans represent a relatively new class of compounds effective in the treatment of migraine. T...
AIM: The aim of this article is to investigate the vascular safety profile of triptans through an an...
Triptans represent the most specific and effective treatment for migraine attacks. Nevertheless, in ...
none8Purpose: We evaluated the incidence, prevalence, and patterns of triptan use with a special foc...
Use of triptans and associated factors in subjects with definite or probable migraine: Prevalence Ra...
Sumatriptan is an agonist of 5-hydroxytryptamine type-1 (5HT1) receptors that is widely used as a mi...
Migraine might be associated with high blood pressure (BP), which can cause more severe and more dif...
Background Safety concerns exist when using triptansto treat patients with cardiac contraindications...
Background: Apart from the underlying cardiovascular (CV) risk associated with migraine, both tripta...
Objective. To examine the association between the cardiovascular (CV) risk factors and triptans use ...
The article highlights the issues of safety when using triptans in the treatment of migraine and the...
The efficacy and safety of triptans in the absence of contraindications have been proved. Neverthele...
AbstractBackgroundIdentifying migraineurs by triptan utilization we studied risk for stroke in migra...
The incidence of stroke, cardiovascular events, and death among 63,575 patients with migraine was co...
Triptans are an established treatment for acute migraine attacks. By activating 5HT1B/1D receptors t...
The triptans represent a relatively new class of compounds effective in the treatment of migraine. T...
AIM: The aim of this article is to investigate the vascular safety profile of triptans through an an...
Triptans represent the most specific and effective treatment for migraine attacks. Nevertheless, in ...
none8Purpose: We evaluated the incidence, prevalence, and patterns of triptan use with a special foc...
Use of triptans and associated factors in subjects with definite or probable migraine: Prevalence Ra...
Sumatriptan is an agonist of 5-hydroxytryptamine type-1 (5HT1) receptors that is widely used as a mi...
Migraine might be associated with high blood pressure (BP), which can cause more severe and more dif...